Med Business World

Your source for healthcare business


Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

MilestoneĀ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). PVST is a condition characterized by an abnormality in the…